🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the battle against superbug strains of the pathogen, according to researchers.

An International Challenge

Gonorrhoea infections are increasing globally, with figures suggesting more than 82 million infections per year. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune development in the context of growing infection rates, escalating drug resistance and the extremely scarce treatment choices at this time.”

Health officials are deeply concerned about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance showed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Secure Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Scientists believe that specific application of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Outcomes and Global Access

Based on findings published in a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which combines an injection and a pill. The research involved over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the ability to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have expressed optimism. The availability of a easy-to-administer therapy of this kind is seen as a "critical tool" for gonorrhoea control. This is viewed as vital to lessen the impact of the infection for individuals and to halt the transmission of untreatable gonorrhoea globally.